New research indicates that patients who discontinue popular slimming jabs like semaglutide or tirzepatide tend to recover shed pounds much more quickly than those who end conventional lifestyle plans.
Findings released in a leading medical journal points out that while obese individuals often shed a large proportion of their total mass while on the medication, the weight returns at an average rate of 0.8 kg per month upon discontinuation.
"Users purchasing such drugs should be cognizant of the danger of quick rebound weight gain when the medication concludes," stated lead investigator Dr. Susan Jebb.
That rate of regain means a return to original mass in about 18 months.
Analyzing Treatments
The study, which examined dozens of studies involving over 9,000 of patients, compared the results of these new drugs with other pills.
Scientists point out that individuals who lose weight through diet and exercise typically see a less rapid weight regain—around 100 grams monthly—post-intervention.
The Reason for the Quick Regain
Nutrition scientists propose the mechanism of the jabs accounts for the heightened rebound.
The injections copy a body's own chemical called GLP-1, which moderates appetite.
"Sustained high doses of GLP-1 levels far above than the body's typical production could lead to the body to generate a reduced amount of its own natural hormone, and may also reduce sensitivity to its effects," noted Dr. Adam Collins, a dietetics expert.
"Withdrawal of this GLP-1 'fix' results in hunger is unsuppressed, making excessive eating a significant risk."
A Lifelong Issue?
Medical guidelines advise the jabs for individuals with obesity-related medical conditions, alongside prescribed diet and exercise modifications.
Many experts say that, considering the high risk of weight regain, the treatment might need to be life-long.
This opinion is echoed by drug manufacturers, who note that the results "underscore the persistent character of excess weight," similar to managing conditions like hypertension.
User Testimonies
People who have stopped the medication report a sudden resurgence of hunger.
"I experienced a switch activating and you're instantly ravenous," described an individual.
The struggle is worsened if individuals have not adopted sustainable lifestyle or habit changes during therapy.
Significant Interest
Survey data indicate that millions of adults in the UK have used weight-loss jabs in the past year, with desire being substantial.
- Use is greater among females compared to men.
- The middle-aged age group shows the highest usage rates.
- A large proportion access the medications through private prescriptions rather than public health services.
Ultimately, clinicians caution that while GLP-1 drugs are potent tools for shedding pounds, they are not a magic solution and long-term success hinges on ongoing behavioural management.
